Cardinal Health Bets Big on Urology with $1.9 Billion Acquisition

In a major strategic move, healthcare distributor Cardinal Health is making a nearly $2 billion wager to accelerate its growth in the lucrative specialty care market. The company has entered into a definitive agreement to acquire a majority stake in Solaris Health, the leading urological management services organization (MSO) in the United States.

The transaction, valued at approximately $1.9 billion in cash, will see Cardinal Health secure roughly 75% ownership of Solaris. This acquisition represents a significant expansion of the company’s existing multi-specialty platform, instantly adding a network of more than 750 healthcare providers across over 250 practice locations in 14 states.

Strategic Expansion Amid Market Pressures

This substantial investment underscores Cardinal Health’s strategic ambition to solidify a leadership position within the high-growth specialty care sector, with a particular focus on urology. While the deal was initially announced in August, it garnered renewed analyst attention this past Friday. The acquisition is anticipated to finalize by the end of calendar year 2025, pending the receipt of necessary regulatory approvals.

The move comes at a pivotal time for the healthcare giant. Despite the strategic optimism, Cardinal Health’s stock recently faced significant selling pressure following its quarterly earnings release on August 12. The company reported adjusted earnings per share (EPS) of $2.08, surpassing analyst expectations of $2.03. However, revenue of $60.2 billion fell short of market forecasts, triggering a sharp decline of over 11% in after-hours trading.

Should investors sell immediately? Or is it worth buying Cardinal Health?

Management Confidence and Analyst Outlook

Undeterred by the short-term market reaction, Cardinal Health’s management has expressed strong confidence in its long-term trajectory. The company has notably raised its financial guidance for fiscal year 2026. It now projects adjusted EPS to land between $9.30 and $9.50, marking a substantial 13% to 15% increase from its prior forecast.

Market experts have largely maintained a positive outlook on the company’s future. Analyst sentiment is broadly described as optimistic, with the average recommendation hovering around “Buy.” This confidence appears rooted in the belief that Cardinal Health will successfully navigate upcoming challenges, including the expiration of its OptumRx contract, by leveraging growth in its pharmaceutical segment and strategic acquisitions like Solaris Health.

The coming months will be critical in determining whether this multi-billion dollar strategic acquisition delivers the intended growth catalyst and helps propel the company’s shares out of their recent weakness.